目的 探究三味檀香胶囊联合替格瑞洛治疗冠心病的临床疗效。方法 选取2013年1月—2015年1月在延安市人民医院接受治疗的冠心病患者94例，根据随机数字表法分成对照组和治疗组，每组各47例。对照组患者口服替格瑞洛片，起始剂量为单次负荷剂量180 mg/d，7 d后调整为90 mg/d进行维持治疗。治疗组在对照组基础上口服三味檀香胶囊，3粒/次，2次/d。所有患者均治疗4周。观察两组的临床疗效，比较治疗前后两组的超敏C-反应蛋白（hs-CRP）和白细胞介素-6（IL-6）的变化。结果 治疗后，对照组和治疗组的心绞痛疗效总有效率分别为87.23%、95.74%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者hs-CRP和IL-6的水平均显著降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 三味檀香胶囊联合替格瑞洛治疗冠心病具有较好的临床疗效，能改善临床症状，降低炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Sanwei Tanxiang Capsules combined with ticagrelor in treatment of coronary heart disease. Methods Patients (94 cases) with cerebral infarction in Yan'an People's Hospital from January 2013 to January 2015 were divided into the control and treatment groups by random number table, and each group had 47 cases. Patients in the control group were po administered with Ticagrelor Tablets, starting dosage was 180 mg/d, and the dosage was adjusted to 90 mg/d after 7 d. Patients in the treatment group were po administered with Sanwei Tanxiang Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the efficacies were evaluated, and the levels of hs-CRP and IL-6 in two groups were compared. Results After treatment, the clinical efficacies of angina pectoris in the control and treatment groups were 87.23% and 95.74%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of hs-CRP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sanwei Tanxiang Capsules combined with ticagrelor has the clinical curative effect in treatment of coronary heart disease, and can improve clinical symptoms, reduce the levels of inflammatory factors which has a certain clinical application value.